Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DGD · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| DGD | EXPERIMENTAL | - |
| SOC | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DGD | DRUG | Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application. |
Inclusion Criteria: 1. Males and females between 4 years to 55 years of age, 2. Thermal burns caused by fire/flame, scalds or contact, 3. Deep partial thickness (mixed deep dermal) and/or full thickness (3°) burn wounds ≥ 5% and ≤ 30% Total Body Surface Area (TBSA); all these wounds must receive st...
DGD is an investigational small molecule used for enzymatic debridement in patients with burns. It is being developed to remove dead or damaged tissue from burn wounds as part of the standard of care. The drug is still in clinical development and has not been approved by regulatory authorities.
DGD is being developed by MediWound Ltd., a biopharmaceutical company traded on the Nasdaq under the ticker MDWD. The company is conducting clinical trials to evaluate the safety and efficacy of DGD for burn debridement.
DGD is in Phase 3 clinical development for burn debridement. A Phase 3 study has been completed, along with an earlier Phase 2 feasibility study. The drug remains investigational and is not yet approved for commercial use.
DGD has been studied in two completed clinical trials. The Phase 3 trial NCT00324311 enrolled 182 patients with burns across multiple countries, comparing enzymatic debridement to standard of care. The Phase 2 trial NCT00898521 enrolled 36 patients with partial thickness burns in India and Israel.
DGD is also known as NexoBrid, a name used for the same investigational enzymatic debridement agent. Both names refer to the product being developed by MediWound Ltd. for the treatment of burn wounds.